Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate
According to a recent press release from the Pennsylvania-based Marinus Pharmaceuticals, the Company is reporting positive results of its phase 2 study of "ganaxolone," an investigational GABAA modulator for patients…